Skip to main content

Taggar

andningsvägar

cancer

diabetes

forskning & utveckling

hjärta/kärl

ledning

mage/tarm

neurovetenskap

AstraZeneca 219 forskning & utveckling 110 cancer 101 hjärta/kärl 80 diabetes 58 andningsvägar 26 mage/tarm 14 neurovetenskap 11 fda 9 onkologi 8 seroquel 7 delårsrapport 7 infektion 7 akut kranskärlssjudom 6 forskning 6 astma 6 Observationsstudie 6 medimmune 6 forxiga 5 vandetanib 5 ledning 5 bokslutsrapport 5 naloxegol 5 motavizumab 5 RWE 5 egfr-testning 5 influensavaccin 5 fostamatinib 4 tc-5214 4 ledgångsreumatism 4 bristol-myers squibb 4 olaparib 4 antibiotika 4 seroquel xr 4 karolinska institutet 4 fluenz 4 lungcancer 3 subvention 3 styrelsen 3 vimovo 3 anders ekblom 3 Tagrisso 3 produkt 3 slusg 3 kroniskt obstruktiv lungsjukdom 3 osimertinib 3 selumetinib 3 antibiotikaresistens 3 japan 3 egentlig depression 3 astra tech 3 pathos 3 CVD-REAL 3 gefitinib 3 crestor® 3 tyskland 2 läkemedelsförmånen 2 återfall 2 mdd 2 samarbete 2 bydureon 2 ticagrelor 2 astrazenca 2 benralizumab 2 individanpassad behandling 2 epanova 2 life science 2 acalabrutinib 2 saturn 2 kina 2 smärta 2 Real World evidence 2 caprelsa 2 typ2diabetes 2 klopidogrel 2 entocort 2 registerstudie 2 opioider 2 ardea biosciences 2 byetta 2 seroquel xr (quetiapin fumarat) 2 slusg stipendium 2 patenttvist 2 confirm 2 Brilique 2 seroquel xl 2 almedalen 2 targacept 2 recentin 2 kvartalsrapport 2 axanum 2 fulvestrant 2 beslut 1 2009 annual scientific meeting in philadelphia 1 egfr-muterad 1 tobias ankner 1 bioläkemedel 1 bypass 1 läkemedel 1 skelettmetastaser 1 non-executive director 1 hha 1 flumist 1 tlv 1 lesinurad 1 durvalumab 1 internationell konkurrens 1 formuleringspatent 1 exenatide 1 målstyrt läkemedel 1 kombiglyze xr 1 mikael agaton 1 ny indikation 1 stroke 1 pegasus 1 patent 1 barninfluensavaccin 1 influensanässpray 1 u.s. food and drug administration (fda) 1 zibotentan 1 berzeliussamlingen 1 generiskt esomeprazolmagnesium 1 sponsring 1 eurika 1 aks 1 pris läkemedel 1 asco 1 zactima (vandetanib) 1 styrelseordförande 1 produktion 1 DAISY 1 typ 2-diabetes 1 blodsockerkontroll 1 avancerad hormonkänslig bröstcancer 1 mrsa 1 lund 1 syntetisk kemi 1 stipendieprogram 1 r&d 1 nässprayvaccin 1 den amerikanska läkemedelsmyndigheten 1 förstoppning 1 dapagliflozin 1 apotex inc (notice of compliance 1 lesinurab 1 forsknings - och utvecklingscentra 1 årsredovisning 2011 1 immunoterapier 1 tre strategiska centra 1 komboglyze 1 moventig 1 mcrc 1 kolorektalcancer 1 ldl-c 1 inflammation 1 nytt läkemedel lungcancer 1 grymt fett 1 hjärt-och kärlsjukdom 1 pluto-studien 1 patologi 1 first studien 1 avancerad bröstcancer 1 egfr mutation 1 forskningsportfölj 1 högkostnadsskyddet 1 kastrationsresistent 1 moderna therapeutics 1 journal of clinical oncology 1 hans andersson 1 päivi tolstoy 1 ceftarolinfosamil 1 ordnat införande Almedalen 1 EGFR 1 antaros 1 fas 3-studie 1 sekundärprevention 1 citizens petition 1 hälsoekonomiska data 1 anastrozol 1 arbetsmarknadsdagar 1 motivationsstöd 1 Lynparza 1 ovarian cancer 1 bakterier 1 varumärkta generika 1 ämnesomsättningssjukdomar (emdac) 1 kol 1 vaccinet 1 roger henriksson 1 bröstcancer utmärkelse 2012 1 astrazeneca lund 1 hudinfektioner 1 forskarstipendium 1 myalept 1 azd9773 1 sumitomo 1 stipendier 1 alzheimers 1 vimovotm 1 non-small cell lung cancer 1 bevacizumab 1 Uppsala Clinical Research Center 1 konkurrenskraften 1 opioidbehandling 1 usa 1 lipodystrofi 1 citizen petitions 1 e-brilique 1 CVD-REAL Nordic 1 produktionsanläggning 1 jonas bergh 1 jan lundberg 1 denosumab 1 bioventurehub 1 noc) 1 blodförgiftning 1 läkemedelsforskning 1 kanadensiska hälsovårdsministeriet 1 subventioner 1 cancerregister 1 max planck institute 1 corporate 1 hälsoekonomi 1 kranskärlsjukdom 1 h1n1 1 mobiltelefonapplikation 1 per hamid ghatan 1 pfizer 1 lungcancersymtom 1 caz-avi 1 tonårshjärnan 1 metabola sjukdomar 1 biohub 1 antidepressiva läkemedel 1 farxiga 1 läkemedelsforskningen 1 cediranib 1 generiska läkemedel 1 behandling lungcancer 1 toprol-xl 1 skatteärende 1 invasiv behandling 1 cardiologföreningen 1 kyntheum 1 non-small-cell lungcancer 1 glp-1 agonister 1 blodsockerfall 1 savor 1 gonorré 1 SUPPORT-studien 1 certriad 1 monoterapi 1 Imfinzi 1 hormonresistent 1 scilifelab 1 livskvalitet lungcancer 1 david brennan 1 prismodell 1 atac 1 karolinska universitetssjukhuset 1 astma/kol 1 kvalitetsregister 1 elisabeth björk 1 arimidex 1 patientstöd 1 artros 1 influensa 1 zinforo 1 translationell 1 leif johansson 1 quetiapin fumarat 1 per alfredsson 1 faslodex (fulvestrant) 1 mobil-app 1 patient websida 1 sepsis 1 pegasus-timi 1 delårsrapport januari-september 2011 1 mjukdelsinfektioner 1 hjärinfarkt 1 hjärtinfarkt 1 klinisk forsk 1 egfr positiv 1 nytt läkemedel mot lungcancer 1 advaxis 1 medicon village 1 QTERN 1 exacerbationer 1 årsredovisning 2010 1 eu 1 pozen 1 nda 1 forskare 1 SvFP 1 merck-avtal 1 ämnesomsättningssjukdomar 1 esc 1 the medicines company 1 brodalumab 1 nikotinkanalsblockerare 1 stemi 1 säsongsinfluensavaccin för barn som nässpray 1 metreleptin 1 complete response letter (crl) 1 collaboration 1 avastin 1 depression 1 nsaid 1 xigduo 1 magnus björsne 1 mölndal 1 torrent pharma 1 american college of rheumatology 1 psoriasis 1 NSCLC 1 cytofab 1 kvadrivalent 1 UCR 1 Zavicefta 1 forskarkarriärer 1 amend 1 oic 1 rosuvastatinkalcium 1 amylin 1 äggstockscancer 1 registreringsansökan 1 budesonid 1 diagnostik 1 jupiter-studien 1 jupiter 1 rosuvastatin 1 hyperkolesterolemi 1 merck 1 viktökning 1 schizofreni 1 apollo 1 amylin pharmaceuticals 1 pa 1 norge 1 nya läkemedel 1 iressa 1 grymt fett en filmserie om tonårshjärnan 1 renaissance 5 1 gensekvensering 1 sjukhussjuka 1 remissvar prismodell 1 illumina 1 fluenz tetra 1 delårsrapport januari - mars 1 pascal soriot 1 innovation 1 halvårsresultat 1 ipass 1 mdr-tb 1 right honourable baroness shriti vadera 1 pet 1 renaissance 4 1 sjukhusinfektioner 1 säsongsinfluencavaccin 1 akuta koronara syndrom 1 södertälje 1 yngre forskare 1 strategiska centra 1 antibiotikum 1 produktionschef 1 världsdiabetesdagen 2014 1 saxagliptin 1 halvårsrapport 1 nktr-118 1 gikt 1 opioidorsakad 1 gener 1 patientundersökning 1 healthy heart africa 1 biokemiska markörer 1 ann cairns 1 sommarforskarskola 1 svenska lungcancerstudiegruppen 1 Visa alla taggar
Bydureon EXSCEL trial demonstrates favourable cardiovascular (CV) safety profile and fewer CV events in patients with type-2 diabetes at wide range of CV risk

Bydureon EXSCEL trial demonstrates favourable cardiovascular (CV) safety profile and fewer CV events in patients with type-2 diabetes at wide range of CV risk

Pressmeddelanden   •   Sep 14, 2017 18:27 CEST

​Largest and most inclusive patient population of any GLP-1 CV outcomes trial with 14,500 patients at 687 trial sites across 35 countries Full trial results presented at the annual meeting of the European Association for the Study of Diabetes (EASD) and simultaneously published in the New England Journal of Medicine

AstraZeneca and Aspen enter agreement for remaining rights to anaesthetic medicines

AstraZeneca and Aspen enter agreement for remaining rights to anaesthetic medicines

Pressmeddelanden   •   Sep 14, 2017 08:03 CEST

Agreement builds on 2016 collaboration on commercialisation rights to anaesthetic medicines in markets outside the US

AstraZeneca presents new results identifying severe asthma patients who would benefit most from Benralizumab

AstraZeneca presents new results identifying severe asthma patients who would benefit most from Benralizumab

Pressmeddelanden   •   Sep 11, 2017 10:11 CEST

Further analysis of the Phase III trials, SIROCCO and CALIMA, reinforces benralizumab’s efficacy and identifies more frequent prior exacerbations and/or greater baseline blood eosinophil count as key predictors of an enhanced treatment effect. Findings pave the way for a personalised treatment approach to guide more precise selection of the benralizumab-responsive patient.

Media no image
Media no image
Förpackning märkt SelokenZOC 100 mg kan innehålla fel burk

Förpackning märkt SelokenZOC 100 mg kan innehålla fel burk

Pressmeddelanden   •   Sep 07, 2017 16:52 CEST

Vi vill uppmärksamma patienter som hämtat ut en förpackning med SelokenZOC 100 mg i burk med 100 tabletter, efter april i år, att kontrollera att den burk som ligger i förpackningen verkligen är märkt SelokenZOC 100 mg. Aktuellt varunummer är Vnr 543587, batchnummer VBBN.

Celgene and AstraZeneca provide update on the FUSION clinical trial programme

Celgene and AstraZeneca provide update on the FUSION clinical trial programme

Pressmeddelanden   •   Sep 07, 2017 14:02 CEST

AstraZeneca and MedImmune, its global biologics research and development arm, have been informed by partner Celgene that the US Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a full clinical hold on one trial in the Celgene FUSION programme.

Duaklir significantly improves lung function in COPD patients

Duaklir significantly improves lung function in COPD patients

Pressmeddelanden   •   Sep 07, 2017 08:09 CEST

​Phase III AMPLIFY trial demonstrateda statistically significant improvement in lung function in patients with COPD Study achieved the primary endpoints to support a New Drug Application (NDA) submission

Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma

Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma

Pressmeddelanden   •   Sep 06, 2017 23:05 CEST

AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma

Media no image

AstraZeneca to present data on next generation of biologics at European Respiratory Society International Congress 2017

Pressmeddelanden   •   Sep 04, 2017 08:03 CEST

​AstraZeneca and its global biologics research and development arm, MedImmune, will present new data on its respiratory portfolio and pipeline at the European Respiratory Society (ERS) International Congress, 9-13 September 2017 in Milan, Italy. The breadth and depth of science are reflected in the 48 accepted abstracts.....

AstraZeneca highlights latest advances in lung cancer at the ESMO 2017 Congress

AstraZeneca highlights latest advances in lung cancer at the ESMO 2017 Congress

Pressmeddelanden   •   Aug 31, 2017 08:11 CEST

More than 40 presentations, including data from two pivotal trials selected as late-breaking abstracts for oral presentation in the ESMO Presidential Symposia Phase III PACIFIC data reinforce potential of Imfinzi following US FDA breakthrough therapy designation in locally-advanced (Stage III) unresectable NSCLC

AstraZeneca and Takeda establish collaboration  to develop and commercialise MEDI1341 for Parkinson’s disease
Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer

Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer

Pressmeddelanden   •   Aug 28, 2017 08:03 CEST

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Faslodex (fulvestrant) 500mg as monotherapy for expanded use in women with hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, who have gone through menopause and have not received previous endocrine therapy.

Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack

Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack

Pressmeddelanden   •   Aug 24, 2017 08:03 CEST

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) from treatment with Brilinta (ticagrelor) 60mg twice daily, versus placebo, in patients taking low-dose aspirin but still at high risk of an atherothrombotic event, a major cause of acute coronary syndrome and CV death.

Lynparza receives additional and broad approval in the US for ovarian cancer

Lynparza receives additional and broad approval in the US for ovarian cancer

Pressmeddelanden   •   Aug 17, 2017 21:27 CEST

AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the U.S. and Canada) today announced that the US Food and Drug Administration (FDA) has granted approval for the PARP inhibitor, Lynparza (olaparib).

Media no image

Nordiska registerdata visar att SGLT-2-hämmare, jämfört med andra glukossänkande läkemedel, förknippas med en minskad risk för prematur hjärt-kärlsjukdom och död

Pressmeddelanden   •   Aug 16, 2017 09:00 CEST

Resultat publicerade i The Lancet Diabetes & Endocrinology från observationsstudien CVD-REAL Nordic, baserad på svenska registerdata, indikerar att behandling av typ 2-diabetes med SGLT-2-hämmare i klinisk praxis är associerad med minskad risk för kardiovaskulära insjuknanden, särskilt med dödlig utgång, jämfört med andra glukossänkande läkemedel, även hos patienter utan känd hjärt-kärlsjukdom.

US FDA accepts regulatory submission for acalabrutinib and grants priority review

US FDA accepts regulatory submission for acalabrutinib and grants priority review

Pressmeddelanden   •   Aug 02, 2017 08:04 CEST

AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for the New Drug Application (NDA) for acalabrutinib, a highly-selective, potent, Bruton tyrosine kinase (BTK) inhibitor.

Acalabrutinib granted breakthrough therapy designation by US FDA for the treatment of patients with mantle cell lymphoma

Acalabrutinib granted breakthrough therapy designation by US FDA for the treatment of patients with mantle cell lymphoma

Pressmeddelanden   •   Aug 01, 2017 08:07 CEST

AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib .

Imfinzi granted breakthrough therapy designation by US FDA for patients with locally-advanced unresectable non-small cell lung cancer

Imfinzi granted breakthrough therapy designation by US FDA for patients with locally-advanced unresectable non-small cell lung cancer

Pressmeddelanden   •   Jul 31, 2017 08:04 CEST

Fourth Breakthrough Therapy Designation for an AstraZeneca New Oncology medicine in three years.

Tagrisso significantly improves progression-free survival in the phase III FLAURA trial for lung cancer

Tagrisso significantly improves progression-free survival in the phase III FLAURA trial for lung cancer

Pressmeddelanden   •   Jul 27, 2017 09:19 CEST

AstraZeneca today announced that the Phase III FLAURA trial showed a statistically-significant and clinically-meaningful progression-free survival (PFS) benefit with Tagrisso (osimertinib) compared to current 1st-line standard-of-care treatment......